Neuronetics Inc

Neuronetics, Inc. commercial stage medical technology company, which engages in the designing, developing and marketing products for the patients suffering from psychiatric disorders. It operates through United States and International geographical segments. The firm offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon, and Thomas D. Weldon in April 2003 and is headquartered in Malvern, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Neuronetics reports robust Q4 performance, eyes nurse practitioner opportunities

Neuronetics delivered a strong performance in Q4 2022, showcasing revenue growth, operational achievements, and strategic partnerships.
While facing challenges in managing losses and revenue fluctuations, the company is focused on key initiatives and opportunities for future growth.
By leveraging upcoming opportunities with nurse practitioners and addressing analyst inquiries, Neuronetics aims to navigate challenges and drive sustainable growth in 2023.

Neuronetics Inc reports revenue growth and strategic advancements in Q1 2023

Neuronetics Inc's Q1 2023 performance reflects revenue growth, operational advancements, and strategic initiatives aimed at driving market expansion and financial stability.
While facing challenges in gross margin decline and negative EBITDA, the company's focus on cost management, recovery from merger disruption, and revenue guidance raise position it for future success.
With opportunities in expanded patient access, market growth, and product enhancements, Neuronetics is poised to capitalize on its strengths and navigate challenges effectively in the coming quarters.

Neuronetics reports solid Q2 performance, eyes growth amidst challenges

Neuronetics demonstrated resilience and growth in Q2 2023, with revenue increases and strategic advancements in technology and policy.
While facing challenges from closures and relocations, the company remains focused on financial stability and operational efficiency.
Opportunities lie in new technology clearances, favorable policy changes, and the growing demand for TMS therapy education and services.
Overall, Neuronetics' performance, strengths, challenges, and opportunities position the company for continued growth and market impact.

Neuronetics Inc reports solid Q3 earnings, faces challenges in expenses

Neuronetics Inc (STIM) delivered a strong performance in Q3 2023, showcasing revenue growth and operational advancements.
While facing challenges in aligning revenue with operating expenses, the company maintains a solid financial position and pursues growth opportunities.
By focusing on enhancing patient care standards, expanding market reach, and optimizing financial performance, Neuronetics Inc aims to drive sustainable growth and value creation.

Neuronetics Inc posts record revenue in Q4 2023 earnings call

Neuronetics Inc delivered a strong Q4 performance with revenue growth and achieving positive cash flow for the first time. The company's focus on strategic initiatives, regulatory advancements, and revenue guidance for 2024 indicate a positive trajectory for growth and profitability.

Neuronetics Inc reports revenue growth and strategic partnerships in Q1

Neuronetics Inc's Q1 2024 performance reflects revenue growth, operational efficiency improvements, and a strong financial position.
Strengths include successful programs, strategic partnerships, and growth opportunities in new market segments.
Challenges in system sales and revenue collection highlight areas for improvement, while opportunities in market expansion and revenue growth are promising.
Overall, Neuronetics shows resilience, innovation, and a strategic focus on driving growth and improving patient outcomes.

Neuronetics Inc reports Q2 revenue decline, eyes growth opportunities

Neuronetics Inc faced revenue challenges due to a cybersecurity breach but showed resilience in key areas.
Strategic adjustments and positive program results indicate a focus on growth and market expansion.
Acquisition and new debt facility offer opportunities for future expansion and financial stability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Neuronetics, Inc. is a commercial stage medical technology company, which focuses on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders. It operates through United States and International geographical segments. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon, and Thomas D. Weldon in 1998 and is headquartered in Malvern, PA.

MALVERN, Pa., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release third quarter 2024 financial and operating results prior to market open on Tuesday, November 12, 2024. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.

Neuronetics to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call

Data selected for oral presentation reinforce previous findings on safety and efficacy Data selected for oral presentation reinforce previous findings on safety and efficacy

NeuroStar® Oral Presentation at AACAP 2024 Highlights Largest Study Evaluating TMS Efficacy in Adolescents with Depression

MALVERN, Pa. and TORONTO , Oct. 4, 2024 /PRNewswire/ - Neuronetics, Inc. (NASDAQ: STIM) ("Neuronetics") and Greenbrook TMS Inc. (OTCMKTS: GBNHF) ("Greenbrook") today announced that the Ontario Superior Court of Justice (Commercial List) (the "Court") has granted an interim order (the "Interim Order") in connection with the previously announced statutory plan of arrangement under section 182 of the Business Corporations Act (Ontario) (the "Plan of Arrangement"), pursuant to which, subject to the satisfaction or waiver of all applicable conditions precedent, Neuronetics will acquire all of the issued and outstanding common shares of Greenbrook ("Greenbrook Shares") in an all-stock transaction (the "Arrangement").

Neuronetics and Greenbrook TMS Announce Receipt of Interim Order in Respect of Proposed Arrangement and Provide Details of Shareholder Meetings

Policy update increases access for millions covered by HCSC BlueCross BlueShield policies Policy update increases access for millions covered by HCSC BlueCross BlueShield policies

Health Care Service Corporation Adds First-Line TMS Coverage for Adolescents

Neuronetics announces that TMS coverage has been updated to reduce access barriers for patients with MDD. In line with this, BCBS and Louisiana Medicaid have expanded their TMS coverage.

STIM Stock Likely to Gain From Updated TMS Coverage

BlueCross BlueShield of North Carolina and Louisiana Medicaid Increase Coverage for Patients with Depression BlueCross BlueShield of North Carolina and Louisiana Medicaid Increase Coverage for Patients with Depression

Expanded Health Policies Enhance TMS Therapy Access for Adolescents and Adults

Upgrades improve communication, streamline data management, and strengthen security Upgrades improve communication, streamline data management, and strengthen security

NeuroStar® Releases Software Upgrades to Elevate Patient Care

NeuroStar Is More Than Halfway to Achieving Its Five-Year Goal of Saving Thousands of Lives NeuroStar Is More Than Halfway to Achieving Its Five-Year Goal of Saving Thousands of Lives

NeuroStar Honors Suicide Prevention Month With Milestone Achievement and Powerful Stories

Neuronetics (STIM) announces the acquisition of Greenbrook to provide better care to patients suffering from mental health conditions.

Neuronetics' (STIM) Latest Deal to Aid Mental Health Treatments

Neuronetics (STIM) signs a merger agreement with Greenbrook to acquire all its outstanding shares. The transaction is expected to be closed during the fourth quarter of 2024.

Neuronetics (STIM) Inks a New Merger Agreement With Greenbrook

Neuronetics' (STIM) second-quarter 2024 top-line results reflect lower revenues from NeuroStar Advanced Therapy System and Treatment sessions.

Neuronetics (STIM) Q2 Loss Wider Than Expected, Revenues Fall Y/Y

Neuronetics, Inc. (NASDAQ:STIM ) Q2 2024 Earnings Conference Call August 12, 2024 8:30 AM ET Company Participants Keith Sullivan - President & CEO Steve Furlong - CFO Mark Klausner - IR Conference Call Participants Margaret Andrew - William Blair Adam Maeder - Piper Sandler John Pinney - Canaccord Genuity Danny Stauder - Citizens JMP Operator Good day, and thank you for standing by. Welcome to the Neuronetics second quarter 2024 financial and operating results conference call.

Neuronetics, Inc. (STIM) Q2 2024 Earnings Call Transcript

Greenbrook TMS Inc

On Monday, Neuronetics Inc. STIM, a provider of noninvasive treatments for psychiatric disorders, agreed to acquire Greenbrook TMS Inc. GBNHF in an all-stock transaction.

Noninvasive Treatment Provider Neuronetics Agrees To Merge With Canadian Firm Greenbrook TMS; Reports Q2 Earnings And Guidance Below Expectations

Neuronetics (STIM) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.17 per share a year ago.

Neuronetics (STIM) Reports Q2 Loss, Lags Revenue Estimates

MALVERN, Pa. and TORONTO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (“Neuronetics”) and Greenbrook TMS Inc. (OTCMKTS: GBNHF) (“Greenbrook”) today announced that they have entered into a definitive arrangement agreement (the “Definitive Agreement”) in which Neuronetics will acquire all of the outstanding common shares of Greenbrook in an all-stock transaction.

Neuronetics and Greenbrook TMS Announce Definitive Agreement to Merge

MALVERN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and operating results for the second quarter of 2024.

Neuronetics Reports Record Second Quarter 2024 Financial and Operating Results

MALVERN, Pa., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 55,200 shares of the Company's common stock (RSUs) to sixteen new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as material inducements to their respective employment with the Company.

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

New initiative aims to provide information and resources for teen mental health amidst rising public health concerns New initiative aims to provide information and resources for teen mental health amidst rising public health concerns

NeuroStar Partners With This Is My Brave to Recognize Teen Mental Health Month

MALVERN, Pa., July 30, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it entered into a debt facility of up to $90 million with Perceptive Advisors LLC (Perceptive). Under the term loan, Neuronetics received the first tranche of $50 million at closing. Part of the initial $50 million tranche will be used to pay off, in full, the Company's existing SLR Capital term loan. Upon achieving certain milestones, a second tranche of $15 million will be available until December 31, 2025. Under the third tranche, the Company can request to borrow $25.0 million on or before June 30, 2026.

Neuronetics Announces the Closing of up to $90 Million Senior Secured Credit Facility with Perceptive Advisors

MALVERN, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release second quarter 2024 financial and operating results prior to market open on Monday, August 12th, 2024. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.

Neuronetics to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call

Coverage criteria consistent with recent FDA clearance for NeuroStar TMS Coverage criteria consistent with recent FDA clearance for NeuroStar TMS

Aetna Policy Update Expands TMS Availability for Adolescents With Depression

Medtronic

NeuroOne Medical Technologies Corp

If the prospect of controlling computers and robots with brainpower alone excites you, neurotech stocks are right up your alley. Unfortunately, today's top neurotech company — Elon Musk's Neuralink — remains off-limits to retail investors.

3 Neurotech Stocks Bridging Mind and Machine

NeuroStar, the first and only TMS treatment cleared for adolescents, now covered by Medi-Cal NeuroStar, the first and only TMS treatment cleared for adolescents, now covered by Medi-Cal

California Medicaid Adds TMS Access for 14.8 Million Adolescents and Adults

Updated criteria post-FDA clearance for NeuroStar TMS benefit youth mental health Updated criteria post-FDA clearance for NeuroStar TMS benefit youth mental health

BlueCross BlueShield MI and Cambia Health Solutions Expand TMS Access for Depressed Adolescents

Neuronetics (STIM) announces the nationwide launch of the Better Me Provider (BMP) program developed in collaboration with TMS medical experts. The BMP program will be part of the company's NeuroStar product line.

News for Neuronetics Inc Stock (STIM)